Revenue Growth Driven by Top-Line Expansion
BDX grew Q2 FY2026 revenue 5.2% year-over-year to $4.71B (from $4.48B), suggesting continued demand for its medical device and diagnostics products despite a challenging macro environment.
BECTON DICKINSON & CO is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: BDX reported Q2 FY2026 revenue growth of 5.2% to $4.71B, but swung to a net loss of $311M (EPS -$1.11) driven by a sharp 75.7% collapse in operating income and surging SG&A costs, while the current ratio fell below 1.0x signaling near-term liquidity pressure.
Drawn from management commentary in the Q1 2026 10-Q:
BDX grew Q2 FY2026 revenue 5.2% year-over-year to $4.71B (from $4.48B), suggesting continued demand for its medical device and diagnostics products despite a challenging macro environment.
Operating income fell dramatically from $383M to just $93M, with operating margin compressing from 8.5% to just 2.0%, driven primarily by an 8.6% surge in SG&A expenses to $1.21B and a 7.3% increase in R&D spend to $249M.
BDX swung from a net income of $308M in Q2 FY2025 to a net loss of $311M in Q2 FY2026, a 201% deterioration, resulting in a diluted EPS of -$1.11 versus +$1.07 in the prior year period.
Revenue
$4.71B
++5.22% YoY
EPS (Basic)
$-1.11
-203.74% YoY
Operating Income
$93M
-75.72% YoY
Add BDX to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.